Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19735710 | 0.91 | PDK2 (0.39) | PDK2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL19735431 | 0.91 | PDK2 (0.36) | PDK2 | |
| SCHEMBL808121 | 0.91 | PDK2 (0.48) | PDK2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL19735432 | 0.90 | PDK2 (0.35) | PDK2 | |
| SCHEMBL19735428 | 0.90 | PDK2 (0.35) | PDK2 | |
| SCHEMBL16996418 | 0.89 | PDK2 (0.40) | PDK2PGRMAOBMAOA | |
| SCHEMBL17858646 | 0.88 | PDK2 (0.42) | PDK2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL17854524 | 0.88 | PDK2 (0.44) | PDK2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16996127 | 0.87 | PDK2 (0.41) | PDK2PGRMAOBMAOA | |
| SCHEMBL19735480 | 0.86 | PDK2 (0.33) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9960357-B2 | Spiro-type compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2018-05-01 | — | — | US | disclosed |
| US-9960357-B2 | Spiro-type compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2018-05-01 | — | — | US | disclosed |
| US-20170365787-A1 | SPIRO-TYPE COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2017-12-21 | — | — | US | disclosed |
| US-20170365787-A1 | SPIRO-TYPE COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170365787-A1 | SPIRO-TYPE COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, NR2E3, LEF1 | PDK2 888/4885GABRA1 2796/4885GABRG2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.